<DOC>
	<DOC>NCT02961491</DOC>
	<brief_summary>The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL).</brief_summary>
	<brief_title>Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma</brief_title>
	<detailed_description>MIP-IB12B, the pivotal phase 2 study evaluating efficacy and safety of AZEDRA in patients with malignant relapsed/refractory PPGL, has completed its anticipated enrollment. The purpose of this sub-study, MIP-IB12B-EAP, is to provide expanded access to AZEDRA for newly enrolled subjects with iobenguane-avid metastatic and/or recurrent PPGL and to collect additional safety data.</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Able and willing to provide informed consent/assent and comply with protocol requirements Documented diagnosis of either pheochromocytoma or paraganglioma that was confirmed by histology or other supportive data (e.g. abnormal MIBG diagnostic study or elevated tumor markers) Ineligible for curative surgery for PPGL Failed a prior therapy for PPGL or have no alternative indicated therapy available Have definitive tumor avidity confirmed by the AZEDRA dosimetry dose Life expectancy of at least 6 months per physician Pregnant or nursing females Men or women of childbearing potential and unwilling to use a medically acceptable form of contraception from time of consent until 6 months following last therapeutic dose of AZEDRA Active CNS lesions by CT/MRI within 3 months of informed consent NYHA class IV heart failure, unstable angina pectoris or clinically significant cardiac arrhythmia that poses a risk of syncope or cardiac arrest Prior systemic radiotherapy resulting in marrow toxicity within 3 months of first AZEDRA therapeutic dose Prior iobenguane I 131 therapeutic exposure within 12 weeks of the first planned therapeutic dose Prior administration of wholebody radiation therapy within 12 weeks of the first planned therapeutic dose Prior external beam radiotherapy to &gt; 25% of bone marrow Prior chemotherapy or investigational compound and/or device within 30 days of the dosimetry dose Other active malignancy requiring additional treatment except for superficial cutaneous neoplasms Karnofsky Performance Status &lt; 60 Clinically significant laboratory abnormalities prior to dosing as listed in the protocol (such as blood count abnormalities, liver enzyme abnormalities, and renal dysfunction) Medical history of AIDS/HIV+ Active chronic alcohol abuse, chronic liver disease (not including liver metastases), hepatitis A, B, or C Known allergy to iobenguane that has required medical intervention Receiving a medication which inhibits tumor uptake of iobenguane I 131 Any other condition, that in the opinion of the investigator, may compromise the safety or compliance of the subject</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MIBG</keyword>
	<keyword>Azedra</keyword>
	<keyword>Rare neuroendocrine tumors</keyword>
	<keyword>Iobenguane I 131</keyword>
	<keyword>Progenics</keyword>
</DOC>